Home Cart 0 Sign in  
X

[ CAS No. 337915-79-4 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 337915-79-4
Chemical Structure| 337915-79-4
Chemical Structure| 337915-79-4
Structure of 337915-79-4 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 337915-79-4 ]

Related Doc. of [ 337915-79-4 ]

Alternatived Products of [ 337915-79-4 ]

Product Details of [ 337915-79-4 ]

CAS No. :337915-79-4 MDL No. :MFCD11977373
Formula : C7H9BrN2 Boiling Point : -
Linear Structure Formula :- InChI Key :WQNHSCZQLLEPOM-UHFFFAOYSA-N
M.W : 201.06 Pubchem ID :12198270
Synonyms :

Calculated chemistry of [ 337915-79-4 ]

Physicochemical Properties

Num. heavy atoms : 10
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.14
Num. rotatable bonds : 1
Num. H-bond acceptors : 0.0
Num. H-bond donors : 2.0
Molar Refractivity : 47.85
TPSA : 38.05 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.16 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.59
Log Po/w (XLOGP3) : 1.92
Log Po/w (WLOGP) : 1.89
Log Po/w (MLOGP) : 1.91
Log Po/w (SILICOS-IT) : 1.46
Consensus Log Po/w : 1.76

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.67
Solubility : 0.426 mg/ml ; 0.00212 mol/l
Class : Soluble
Log S (Ali) : -2.34
Solubility : 0.913 mg/ml ; 0.00454 mol/l
Class : Soluble
Log S (SILICOS-IT) : -3.33
Solubility : 0.0932 mg/ml ; 0.000463 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.69

Safety of [ 337915-79-4 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P280-P305+P351+P338 UN#:N/A
Hazard Statements:H317-H319 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 337915-79-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 337915-79-4 ]
  • Downstream synthetic route of [ 337915-79-4 ]

[ 337915-79-4 ] Synthesis Path-Upstream   1~8

  • 1
  • [ 302800-13-1 ]
  • [ 337915-79-4 ]
YieldReaction ConditionsOperation in experiment
93% With zinc In methanol; water at 20℃; for 1 h; A solution of 12a (350 mg, 1.51 mmol), zinc (495 mg, 7.57 mmol), and NH4Cl (810 mg, 15.15 mmol) in MeOH (4 mL)/water (2 mL) was stirred at rt for 1 h. The insoluble material was removed by filtration and neutralized satd NaHCO3 solution. The mixture was concentrated and extracted with EtOAc. The organic layer was separated, washed with water and brine, dried over MgSO4, and concentrated in vacuo to give the title compound as a brown solid (282 mg, 93percent). 1H NMR (400 MHz, DMSO-d6) δ 2.68 (3H, d, J = 4.9 Hz), 4.60 (2H, s), 4.87 (1H, d, J = 4.9 Hz), 6.32-6.58 (3H, m). MS (ESI/APCI) m/z = 202.09 [M+H]+.
78% With iron; ammonium chloride In methanol; water at 75℃; for 12 h; The NH4Cl (18.01g,336 . 7 mmol) of H2O (80 ml) solution is added to 5 - bromo - N - methyl -2 - nitroaniline (10.00 g, 43 . 28 mmol) in MeOH (85 ml) solution, and then the iron powder (9.65 g, 172.8 mmol) added new staff in the mixed solution, 75 °C oil bath is heated under reflux reaction 12 h. The reaction cooling to room temperature, filtered to remove insoluble matter, concentrated under reduced pressure, to the residue add saturated NaCl in aqueous solution (50 ml), then DCM (100 ml × 3) extraction, the combined organic phase, and anhydrous Na2SO4Drying, concentrated under reduced pressure, the crude product separation and purification with silica gel column chromatography (eluent: PE/EtOAc (v/v)=6/1), to obtain the product as a brown solid (6.80 g, 78percent).
73.4% With sodium dithionite In ethanol; water Step B(2-amino-5-bromophenyl)methylamine [00303] To a bright yellow solution of 5-bromo-N-methyl-2-nitroaniline (1.56 g, 6.75 mmol) in EtOH (100 mL) was added dropwise a solution of sodium dithionate (8.35 g, 40.5 mmol) in H20 (80 mL). The resulting pale yellow slurry was filtered and the solid was washed with EtOH. The filtrate was concentrated. The residue was partitioned between EtOAc (100 mL) and water (100 mL). The organic layer was washed with a sat. NaCI solution (100 mL) and concentrated to obtain (2-amino-5-bromophenyl)methylamine (996 mg, 4.95 mmol, 73.4 percent yield) as a brown oil: 1H NMR (400 MHz, DMSO-d6) δ ppm 2.68 (s, 3 H) 4.62 (br. s., 2 H) 4.89 (br. s., 1 H) 6.40 (d, J=2.15 Hz, 1 H) 6.42 - 6.46 (m, 1 H) 6.49 - 6.54 (m, 1 H); ES LC-MS m/z =201.5 (Br79, M+H)+; ES LC-MS m/z =203.4 (Br81, M+H)+.
53% With tin(ll) chloride In ethanol at 70℃; for 3 h; Part B:To compound 229 (5.40 g, 23.4 mmol) in ethanol (200 ml_) was added tin (II) chloride (22.2 g, 117 mmol). The resulting solution was stirred at 7O0C for 3 hours at which time LC-MS indicated that the reaction was complete. The reaction mixture was <n="113"/>concentrated under vacuum. Ice-water was added to the residue, the pH adjusted to 10 with aqueous sodium carbonate and extracted with ethyl acetate. The organic layer was dried over anh sodium sulfate and concentrated under vacuum. Purification by column chromatography (SiO2, 5percent EtOAc/DCM) afforded compound 230 as a yellow oil 2.50 g (53percent). 1H NMR (400 MHz, DMSO-d6) δ 6.50 (dd, 1 H), 6.43 (d, 1 H), 6.38 (d, 1 H)1 4.6 (bs, 2H), 2.68 (d, 3H).
8.36 g With hydrogenchloride; ammonium chloride; zinc In methanol; water at 50℃; Example 47 4- (Benzyloxy) -1- (2-ethyl-l-methyl-lH-benzimidazol-6- yl) pyridin-2 (1H) -one A) 6-Bromo-2-ethyl-l-methy1-lH-benzimidazole A mixture of 5-bromo-N-methyl-2-nitroaniline (10 g) , zinc (14.15 g), NH4C1 (23.15 g) , MeOH (70 ml), 1 M HC1 (10 ml) and water (35 ml) was stirred at 50°C overnight. The mixture was neutralized with saturated NaHCC>3 solution and passed through celite pad to remove the precipitate. After evaporation of the solvent, the mixture was extracted with EtOAc three times. The organic layer was separated, washed with water and brine, dried over MgS04, passed through NH silica pad, and concentrated in vacuo to give an intermediate diamine (8.36 g) as a dark brown oil. The intermediate diamine was dissolved in DMF (160 ml) , and N, N-diisopropylethylamine (15.12 ml), propanoic acid (3.53 ml) and HATU (18.1 g) were added. The mixture was stirred at room temperature for 2 h. The mixture was quenched with brine and extracted with EtOAc five times. The organic layer was separated, dried over MgS04 and concentrated in vacuo. The resulting residue was dissolved in AcOH (70.0 ml), and stirred at 80°C for 1 h. After evaporation of the solvent, the residue was passed through NH silica pad and purified by NH silica gel column chromatography (hexane/EtOAc) . The resulting, solid was washed with IPE/hexane to give the title compound (5.92 g) as a red solid. MS (ESI+) : [M+H]+ 239.0.

Reference: [1] Bioorganic and Medicinal Chemistry, 2016, vol. 24, # 11, p. 2486 - 2503
[2] Patent: CN108689942, 2018, A, . Location in patent: Paragraph 0463; 0468-0469
[3] Patent: WO2012/174312, 2012, A2, . Location in patent: Page/Page column 216-217
[4] Patent: WO2008/82487, 2008, A2, . Location in patent: Page/Page column 111-112
[5] Patent: WO2004/111036, 2004, A1, . Location in patent: Page 21
[6] Patent: WO2004/111046, 2004, A2, . Location in patent: Page/Page column 18-19
[7] Patent: US2010/113461, 2010, A1, . Location in patent: Page/Page column 17
[8] Bioorganic and Medicinal Chemistry Letters, 2010, vol. 20, # 6, p. 1939 - 1943
[9] Patent: WO2008/12623, 2008, A1, . Location in patent: Page/Page column 60-61
[10] Patent: WO2011/12622, 2011, A1, . Location in patent: Page/Page column 68
[11] Patent: WO2011/109277, 2011, A1, . Location in patent: Page/Page column 30-31
[12] Patent: WO2012/21382, 2012, A1, . Location in patent: Page/Page column 30
[13] Patent: US2012/108578, 2012, A1, . Location in patent: Page/Page column 27
[14] Patent: WO2013/105676, 2013, A1, . Location in patent: Page/Page column 143; 144
[15] Patent: WO2014/100734, 2014, A1, . Location in patent: Paragraph 00319
[16] Patent: WO2015/200677, 2015, A2, . Location in patent: Paragraph 00457; 00458
[17] Patent: WO2016/57834, 2016, A1, . Location in patent: Paragraph 000800
[18] Patent: WO2017/69980, 2017, A1, . Location in patent: Paragraph 00418
[19] Patent: WO2017/176960, 2017, A1, . Location in patent: Paragraph 00748
[20] Patent: WO2007/135527, 2007, A2, . Location in patent: Page/Page column 66
  • 2
  • [ 53484-26-7 ]
  • [ 337915-79-4 ]
YieldReaction ConditionsOperation in experiment
96% With platinum on activated charcoal; hydrogen In ethyl acetate at 20℃; for 4 h; To I-36.1 (5.27 g, 22.81 mmol) in ethyl acetate is added platinum on carbon (550 mg) and stirred under hydrogen (5 bar) at r.t. for 4 h. The reaction mixture is filtered through a pad of celite and concentrated. The crude product is used without further purification for the next step. Yield 96percent.
Reference: [1] Patent: US2014/275025, 2014, A1, . Location in patent: Paragraph 0618; 0626
  • 3
  • [ 321-23-3 ]
  • [ 337915-79-4 ]
Reference: [1] Patent: WO2011/12622, 2011, A1,
[2] Patent: WO2011/109277, 2011, A1,
[3] Patent: WO2012/21382, 2012, A1,
[4] Patent: US2012/108578, 2012, A1,
[5] Patent: WO2012/174312, 2012, A2,
[6] Patent: WO2013/105676, 2013, A1,
[7] Patent: WO2014/100734, 2014, A1,
[8] Patent: WO2015/200677, 2015, A2,
[9] Bioorganic and Medicinal Chemistry, 2016, vol. 24, # 11, p. 2486 - 2503
[10] Patent: WO2016/57834, 2016, A1,
[11] Patent: WO2017/69980, 2017, A1,
[12] Patent: WO2017/176960, 2017, A1,
[13] Patent: WO2007/135527, 2007, A2,
[14] Patent: CN108689942, 2018, A,
  • 4
  • [ 367-24-8 ]
  • [ 337915-79-4 ]
Reference: [1] Patent: WO2007/135527, 2007, A2,
  • 5
  • [ 875-51-4 ]
  • [ 337915-79-4 ]
Reference: [1] Patent: US2014/275025, 2014, A1,
  • 6
  • [ 337915-79-4 ]
  • [ 149-73-5 ]
  • [ 53484-16-5 ]
YieldReaction ConditionsOperation in experiment
54.74% With toluene-4-sulfonic acid In toluene for 2 h; Heating / reflux To a solution of intermediate 2 (5g, 21.6mmol) in EtOH (200ml) was added portionwise SnCI2.2H2O (9.8g, 43mmol) and the mixture was heated under reflux for 4 hours and then concentrated under reduced pressure. The residue was treated with water (200ml) and 1N NaOH (100ml). After extraction with CH2CI2, the organic phase was dried over Na2SO4 and concentrated under reduced pressure. The residue was dissolved in toluene (50ml) and trimethylorthoformate (2.6ml, 24 mmol) and ARTS (0.2g) were added and the mixture was heated under reflux for 2 hours and then concentrated under reduced pressure. The residue was purified by chromatography on silica gel eluting with CH2CI2/MeOH (95/5). The title compound was obtained as a cream powder (2.5g, 54.74percent); m.p. 126-128°C.
54.74% With toluene-4-sulfonic acid In toluene for 2 h; Heating / reflux To a solution of intermediate 2 (5g, 21.6mmol) in EtOH (200ml) was added portionwise SnCl2.2H2O (9.8g, 43mmol) and the mixture was heated under reflux for 4 hours and then concentrated under reduced pressure. The residue was treated with water (200ml) and NaOH 1N (100ml). After extraction with CH2CI2, the organic phase was dried over Na2SO4 and concentrated under reduced pressure. The residue was dissolved in toluene (50ml) and trimethylorthoformate (2.6ml, 24 mmol) and ARTS (0.2g) were added and the mixture was heated under reflux for 2 hours and then concentrated under reduced pressure. The residue was purified by chromatography on silica gel eluting with CH2CI2/MeOH (95/5). The title compoundwas obtained as a cream powder (2.5g, 54.74percent); m.p. 126-128°C
Reference: [1] Patent: WO2004/111036, 2004, A1, . Location in patent: Page 21
[2] Patent: WO2004/111046, 2004, A2, . Location in patent: Page/Page column 18-19
[3] Patent: WO2014/100734, 2014, A1, . Location in patent: Paragraph 00320
[4] Patent: WO2015/200677, 2015, A2, . Location in patent: Paragraph 00459; 00460
  • 7
  • [ 337915-79-4 ]
  • [ 530-62-1 ]
  • [ 305790-48-1 ]
Reference: [1] Patent: WO2012/21382, 2012, A1, . Location in patent: Page/Page column 30
[2] Patent: WO2016/57834, 2016, A1, . Location in patent: Paragraph 000821; 000875
  • 8
  • [ 337915-79-4 ]
  • [ 1083181-43-4 ]
Reference: [1] Patent: WO2011/12622, 2011, A1, . Location in patent: Page/Page column 68; 69
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 337915-79-4 ]

Aryls

Chemical Structure| 66584-32-5

[ 66584-32-5 ]

3-Bromo-N-methylaniline

Similarity: 0.92

Chemical Structure| 1150102-47-8

[ 1150102-47-8 ]

6-Bromo-N1-methylbenzene-1,2-diamine

Similarity: 0.90

Chemical Structure| 1575-37-7

[ 1575-37-7 ]

4-Bromobenzene-1,2-diamine

Similarity: 0.86

Chemical Structure| 586-77-6

[ 586-77-6 ]

4-Bromo-N,N-dimethylaniline

Similarity: 0.85

Chemical Structure| 16518-62-0

[ 16518-62-0 ]

3-Bromo-N,N-dimethylaniline

Similarity: 0.85

Bromides

Chemical Structure| 66584-32-5

[ 66584-32-5 ]

3-Bromo-N-methylaniline

Similarity: 0.92

Chemical Structure| 1150102-47-8

[ 1150102-47-8 ]

6-Bromo-N1-methylbenzene-1,2-diamine

Similarity: 0.90

Chemical Structure| 1575-37-7

[ 1575-37-7 ]

4-Bromobenzene-1,2-diamine

Similarity: 0.86

Chemical Structure| 586-77-6

[ 586-77-6 ]

4-Bromo-N,N-dimethylaniline

Similarity: 0.85

Chemical Structure| 16518-62-0

[ 16518-62-0 ]

3-Bromo-N,N-dimethylaniline

Similarity: 0.85

Amines

Chemical Structure| 66584-32-5

[ 66584-32-5 ]

3-Bromo-N-methylaniline

Similarity: 0.92

Chemical Structure| 1150102-47-8

[ 1150102-47-8 ]

6-Bromo-N1-methylbenzene-1,2-diamine

Similarity: 0.90

Chemical Structure| 1575-37-7

[ 1575-37-7 ]

4-Bromobenzene-1,2-diamine

Similarity: 0.86

Chemical Structure| 586-77-6

[ 586-77-6 ]

4-Bromo-N,N-dimethylaniline

Similarity: 0.85

Chemical Structure| 16518-62-0

[ 16518-62-0 ]

3-Bromo-N,N-dimethylaniline

Similarity: 0.85